Patents by Inventor Remy Pujol
Remy Pujol has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10966940Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.Type: GrantFiled: July 22, 2019Date of Patent: April 6, 2021Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Auris Medical AGInventors: Matthieu Guitton, Jean-Luc Puel, Remy Pujol, Jerome Ruel, Jing Wang
-
Publication number: 20180256514Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.Type: ApplicationFiled: November 15, 2017Publication date: September 13, 2018Inventors: Matthieu GUITTON, Jean-Luc PUEL, Remy PUJOL, Jerome RUEL, Jing WANG
-
Patent number: 10001082Abstract: An assembly for a turbojet engine includes a pylon, a nacelle supported by the pylon, and a locking device interposed between the pylon and a cowl of the nacelle. The cowl slides between operating and maintenance positions. The locking device is movable between active and inhibited positions, and the device allows an operation mode in the active position and a maintenance mode in the inhibited position. In particular, the locking device comprises a rocker to maintain the cowl to the pylon, and the rocker includes an inhibiting lever and an activation lever. The inhibiting and activation levers are mounted on a switching shaft of the locking device. The inhibiting lever is set in rotation through an actuator, providing direct access from a bypass flow duct in the active position while the activation lever is set in rotation from the bypass duct in the inhibited position.Type: GrantFiled: December 4, 2014Date of Patent: June 19, 2018Assignee: AIRCELLEInventors: Olivier Conet, Rémi Pujol, Michel Jean, Jean-Francois Thouement
-
Publication number: 20170224638Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.Type: ApplicationFiled: September 7, 2016Publication date: August 10, 2017Inventors: Matthieu GUITTON, Jean-Luc PUEL, Remy PUJOL, Jerome RUEL, Jing WANG
-
Patent number: 9463168Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.Type: GrantFiled: June 2, 2015Date of Patent: October 11, 2016Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), AURIS MEDICAL AGInventors: Matthieu Guitton, Jean-Luc Puel, Remy Pujol, Jerome Ruel, Jing Wang
-
Publication number: 20150292436Abstract: An assembly for a turbojet engine includes a pylon, a nacelle supported by the pylon, and a locking device interposed between the pylon and a cowl of the nacelle. The cowl slides between operating and maintenance positions. The locking device is movable between active and inhibited positions, and the device allows an operation mode in the active position and a maintenance mode in the inhibited position. In particular, the locking device comprises a rocker to maintain the cowl to the pylon, and the rocker includes an inhibiting lever and an activation lever. The inhibiting and activation levers are mounted on a switching shaft of the locking device. The inhibiting lever is set in rotation through an actuator, providing direct access from a bypass flow duct in the active position while the activation lever is set in rotation from the bypass duct in the inhibited position.Type: ApplicationFiled: December 4, 2014Publication date: October 15, 2015Inventors: Olivier CONET, Rémi PUJOL, Michel JEAN, Jean-Francois THOUEMENT
-
Publication number: 20150265552Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.Type: ApplicationFiled: June 2, 2015Publication date: September 24, 2015Inventors: GUITTON, Jean-Luc PUEL, Remy PUJOL, Jerome RUEL, Jing WANG
-
Patent number: 9072662Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.Type: GrantFiled: July 31, 2014Date of Patent: July 7, 2015Assignees: Auris Medical AG, Institut National De La Sante et de La Recherche MedicaleInventors: Matthieu Guitton, Jean-Luc Puel, Remy Pujol, Jerome Ruel, Jing Wang
-
Publication number: 20150057360Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.Type: ApplicationFiled: July 31, 2014Publication date: February 26, 2015Inventors: Matthieu GUITTON, Jean-Luc PUEL, Remy PUJOL, Jerome RUEL, Jing WANG
-
Publication number: 20140017172Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.Type: ApplicationFiled: July 9, 2013Publication date: January 16, 2014Inventors: Matthieu GUITTON, Jean-Luc Puel, Remy Pujol, Jerome Ruel, Jing Wang
-
Patent number: 8507525Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.Type: GrantFiled: April 1, 2010Date of Patent: August 13, 2013Assignee: Auris Medical AGInventors: Matthieu Guitton, Jean-Luc Puel, Remy Pujol, Jerome Ruel, Jing Wang
-
Patent number: 8268866Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, sudden deafness, or other cochlear excitotoxic-inducing occurrence.Type: GrantFiled: March 29, 2004Date of Patent: September 18, 2012Inventors: Matthieu Guitton, Jean-Luc Puel, Remy Pujol
-
Publication number: 20100254907Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.Type: ApplicationFiled: April 1, 2010Publication date: October 7, 2010Inventors: Matthieu GUITTON, Jean-Luc Puel, Remy Pujol, Jerome Ruel, Jing Wang
-
Publication number: 20100173874Abstract: The invention features methods and devices for local delivery of agents that modify glutamate-mediated neurotransmission to the inner ear for treatment of inner ear disorders caused by glutamate-induced hearing loss and/or tinnitus.Type: ApplicationFiled: July 30, 2009Publication date: July 8, 2010Inventors: Jean-Luc Puel, Remy Pujol, Yves Christen
-
Patent number: 7589110Abstract: The invention features methods and devices for local delivery of agents that modify glutamate-mediated neurotransmission to the inner ear for treatment of inner ear disorders caused by glutamate-induced hearing loss and/or tinnitus.Type: GrantFiled: September 6, 2002Date of Patent: September 15, 2009Assignees: Durect Corporation, InsermInventors: Jean-Luc Puel, Remy Pujol, Yves Christen
-
Publication number: 20070015727Abstract: The invention features methods and devices for local delivery of agents that modify glutamate-mediated neurotransmission to the inner ear for treatment of inner ear disorders caused by glutamate-induced hearing loss and/or tinnitus.Type: ApplicationFiled: September 6, 2002Publication date: January 18, 2007Inventors: Jean-Luc Puel, Remy Pujol, Yves Christen
-
Publication number: 20060063802Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.Type: ApplicationFiled: September 28, 2005Publication date: March 23, 2006Inventors: Matthieu Guitton, Jean-Luc Puel, Remy Pujol, Jerome Ruel, Jing Wang
-
Publication number: 20050214338Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, sudden deafness, or other cochlear excitotoxic-inducing occurrence.Type: ApplicationFiled: March 29, 2004Publication date: September 29, 2005Inventors: Matthieu Guitton, Jean-Luc Puel, Remy Pujol